anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
LINC00355 is involved in the tumorigenesis of several types of cancer. We verified that LINC00355 is upregulated in gastric cancer (GC) and contributes to GC cells' proliferation and metastasis. RNA sequencing (RNA-seq) and rescue assays suggested that LINC00355 controls gastric carcinogenesis by regulating the expression of cell division cycle 42 (CDC42) guanosine triphosphatase (GTPases), thereby activating their downstream pathways. Most previous studies have shown that LINC00355 acts as a ceRNA by sponging miRNAs to modulate downstream gene expression. Our group focus on epigenetic regulatory potential of LINC00355 in gene expression. Mechanistically, LINC00355 binds to p300 histone acetyltransferase, specifying the histone modification pattern on the CDC42 promoter to activate CDC42 transcription, thereby altering GC cell biology. In addition, HNRNPA2B1, which is upregulated by LINC00355, recognizes the N6-methyladenosine (m6A) sites of CDC42 and enhances the stability of CDC42 mRNA transcripts. Therefore, LINC00355 is mechanistically, functionally, and clinically oncogenic in GC cells.
Neuroinflammation and apoptosis play critical roles in the pathogenesis of Alzheimer's disease (AD), which is responsible for most cases of dementia in the elderly people. Gallic acid is a phenolic compound with radical scavenging, anti-inflammatory and anti-apoptotic activities. This study aimed to explore the protective effects of gallic acid on LPS-induced spatial memory impairment and find the underlying mechanisms. Gallic acid was orally administered (100 mg/kg) to male Wistar rats for 12 days. LPS was injected intraperitoneally at a dose of 1 mg/kg on days 8-12. Morris water maze paradigm was used to evaluate spatial learning and memory. The mRNA level of nuclear factor kappa B (NF-κB), tumor necrosis factor-α (TNF-α) and Caspase 3, lipid peroxidation and total thiol level was assessed in the rat hippocampus. Neuronal loss and histological changes were also evaluated in the brain. LPS treatment resulted in spatial learning and memory impairment, upregulation of NF-κB, TNF-α, and Caspase 3 mRNA expression, increased lipid peroxidation, decreased total thiol level, and neuronal loss in the hippocampus. Moreover, treatment with gallic acid at a dosage of 100 mg/kg ameliorated memory decline, reduced the mRNA level of NF-κB, TNF-α, and Caspase 3, decreased lipid peroxidation and increased total thiol level in the hippocampus. Gallic acid also prevented LPS-induced neuronal loss and histological changes in the brain. Conclusively, our study demonstrated that gallic acid exerts neuroprotective effect against LPS-induced memory decline in rats. This outcome could be due to anti-inflammatory, antioxidant, and anti-apoptotic activities of gallic acid.
The present invention relates to a compressed tablet core comprising dolutegravir sodium of formula (I), wherein the tablet core comprises granules and a tablet base, and to a coated tablet comprising said compressed tablet core. The granules of the tablet core comprise dolutegravir sodium of formula (I), and low to medium viscosity polyvinylpyrrolidone (PVR) binders. Additionally, the granules comprise one or more specific fillers selected from the group consisting of mannitol, sorbitol, lactose, dibasic calcium phosphate, and microcrystalline cellulose (MCC), and one or more disintegrants selected from the group consisting of crospovidone (cross-linked polyvinylpyrrolidone), croscarmelose sodium, and sodium starch glycolate. The tablet base comprises specific binders selected from the group consisting of hypromellose, hydroxyethylcellulose (HEC), sodium carboxymethylcellulose (NaCMC), and high viscosity PVP binders. The tablet base additionally comprises one or more disintegrants selected from the group indicated above for the granules. The present invention also relates to a process for preparing said tablet core, and to the compressed tablet core or the coated tablet for use in the treatment of human immunodeficiency virus (HIV-1) infection.
Local tolerability reactions (including blistering and skin desquamation) and hypersensitivity adverse reactions (including urticaria) have been observed with topical tazarotene. Application of tazarotene cream may cause excessive irritation in the skin of certain sensitive individuals. Some individuals may experience excessive pruritus, burning, skin redness or peeling. If these effects occur, the medication should either be discontinued until the integrity of the skin is restored, or the dosing should be reduced to an interval the patient can tolerate. However, efficacy at reduced frequency of application has not been established. Alternatively, patients with psoriasis who are being treated with the 0.1% concentration can be switched to the lower concentration. Frequency of application should be closely monitored by careful observation of the clinical therapeutic response and skin tolerance. Therapy can be resumed, or the drug concentration or frequency of application can be increased as the patient becomes able to tolerate treatment.

Concomitant topical medications and cosmetics that have a strong drying effect should be avoided. It is also advisable to "rest" a patient's skin until the effects of such preparations subside before use of tazarotene cream is begun.

Tazarotene cream, should not be used on eczematous skin, as it may cause severe irritation. Weather extremes, such as wind or cold, may be more irritating to patients using tazarotene cream.
PURPOSE: A cosmetic composition containing Filipendula formosa extract is provided to suppress MMP-1 generation and melanogenesis and to ensure collagen synthesis and antioxidation. CONSTITUTION: A cosmetic composition for anti-aging or antioxidation contains Filipendula formosa extract as an active ingredient. A cosmetic composition for skin regeneration and anti-winkling contains the Filipendula formosa extract as an active ingredient. A cosmetic composition for skin whitening and skin moisturization contains the Filipendula formosa extract as an active ingredient. The Filipendula formosa extract is contained in 0.00001-30.0%(w/w) based on total weight of the composition. The Filipendula formosa extract is isolated using water, anhydrous or hydrous low alcohol of 1-4 carbon atoms, glycerin, acetone, ethyl acetate, butyl acetate, chloroform, diethyl ether, hexane, or mixture thereof. The cosmetic composition is used in the form of a solution, suspension, paste, gel, cream, lotion, powder, soap, oil, spray, or mixture thereof.
Patients undergo spectroscopic magnetic resonance imaging-guided dose-escalated radiation therapy daily for the first 5 days of every week (Monday - Friday) over 6 weeks. Patients also receive standard of care temozolomide PO daily during radiation therapy for up to 42 days.
This study protocol will measure the efficacy of deep anesthesia, until burst suppression rate of 80% or more measured with Bi-spectral Index (BIS), with the volatile anesthetic Isoflurane. The investigators will select 30 subjects. The participants will be separated into 2 arms of 15 individuals. One arm called ISOAD will keep the oral treatment with antidepressants. The second arm, called ISO, will do a washout of any oral medications for depression. Both groups will go under six sessions, once per week, of deep anesthesia and will be followed up for 6 months to evaluate the survival of the antidepressant effect, if any effect happens. Before the anesthesia occurs, blood samples will be drawn to measure Brain-derived neurotrophic factor and investigators will apply depression rating scales such as MADRS and Hamilton - 17 , Young mania Scale, UKU scale for side effects, electroencephalogram will be recorder to be compared with the data shown on BIS. All the anesthesia procedure will be done with induction with propofol, fentanyl and muscular relaxant, to facilitate the tracheal intubation and compliance with the mechanical ventilator,based on body weight in standard dosages. Isoflurane will be set to 2,4% ( 2 cam) until Burst suppression rate \>80% is achieve. Then the anesthesia will be maintained for 15 minutes, then the flow of anesthetic gas will be ended and the patient will be allowed to awake and discharged home when the anesthesiologist decide based on Aldrete Kroulik scale. After the 6th session the participant will return in one week to final evaluation. All the patients that shows improvement in depression scores will enter the phase 2 with one visit every 15 days for 2 months and then once a month until the 6th month. The non responders of the ISO group will start oral antidepressant sertraline to evaluate any potentialization effect of the intervention and be allocated in ISOPOT group. Those from ISOAD group (Isoflurane plus oral antidepressants) that did not respond to the intervention will be discontinued from the study and their data used in the study as non-responders. Those from ISOPOT group that did not improve their depression scores after 4 weeks will be discontinued from the study and the data computed as non-responders.
Disclosed are compositions that include anti-CD74 immunoconjugates and optionally a therapeutic and/or diagnostic agent. In preferred embodiments, the immunoconjugates comprise one or more anti-CD74 antibodies or antigen-binding fragments thereof, conjugated to a carrier such as a polymer, nanoparticle, complex or micelle. Also disclosed are methods for preparing the immunoconjugates and using the immunoconjugates in diagnostic and therapeutic procedures. In certain preferred embodiments, the therapeutic methods comprise administering to a subject with a CD74-expressing disease an anti-CD74 immunoconjugate and thereby inducing cell death of CD74-expressing cells. In more preferred embodiments, the CD74 immunoconjugate is capable of inducing cell death in the absence of any other therapeutic agent, although such agents may be optionally administered prior to, together with or subsequent to administration of the anti-CD74 immunoconjugate. The compositions may be part of a kit for administering the anti-CD74 immunoconjugates or compositions.
The present invention provides a class of substituted indene compounds and their pharmaceutically acceptable salts which possess selective estrogen receptor modulator (SERM) activity and are thus useful in the treatment of osteoporosis and cardiovascular disease, particularly hyperlipidemia in women. The compounds possess the structure in which R1 is hydrogen, hydroxy, alkoxy, phenylcarbonyloxy, alkylcarbonyloxy, or alkylsulfonyloxy. R2 is hydrogen, hydroxy, halo, alkoxy, phenylcarbonyloxy, alkylcarbonyloxy, or alkylsulfonyloxy. R3 is 1-piperidinyl, 1-pyrrolidinyl, methyl-1-pyrrolidinyl, dimethyl-1-pyrrolidinyl, 4-morpholino, dimethylamino, diethylamino, diisopropylamino, or 1-hexa-methyleneimino, and n is 2 or 3. The dashed line bond between the carbon atoms at positions 1 and 2 of the indene nucleus represent an optional double bond with the proviso that when the double bond is absent, the parenthetic hydroxy group at position 1 is present and vice versa. Certain 2,3-dihydro-1H-indene precursors to the disclosed indene compounds also possess SERM activity and are useful for the same purposes.
A compound of formula I or a pharmaceutically acceptable salt thereof: wherein R1 is deuterium or hydrogen. The deuterated valproic acid compound of formula I is selected from 2-[(2,2,3,3-D4)propyl](4,4,5,5-D4)pentanoic acid and 2-[(2,2,3,3-D4)propyl](2,4,4,5,5-D5)pentanoic acid and salts thereof, preferably sodium salts. Also disclosed is a pharmaceutical composition comprising the deuterated valproic acid compound of formula I and a pharmaceutical vehicle. The deuterated valproic acid compounds of formula I are for use in the treatment of conditions associated with excess fibrin, thrombus formation, fibrosis, bipolar disorders, migraine headaches, epilepsy or conditions wherein inhibition of histone deacetylase (HDAC) is beneficial. A method of treating an abnormal condition associated with excess fibrin, thrombus formation and/or fibrosis comprising administering a therapeutically effective amount of the deuterated valproic acid compound of formula I is also disclosed. Methods of treating bipolar disorder, migraine headaches or epilepsy are also disclosed. The compounds of the invention exhibit reduced formation of the toxic 4-ene metabolite and therefore have reduced hepatotoxicity.
In recent years, the incidence of metabolic syndrome (MS) has increased due to lifestyle-related factors in developed countries. MS represents a group of conditions that increase the risk of diabetes, cardiovascular diseases, and other severe health problems. Low-grade chronic inflammation is now considered one of the key aspects of MS and could be defined as a new cardiovascular risk factor. Indeed, an increase in visceral adipose tissue, typical of obesity, contributes to the development of an inflammatory state, which, in turn, induces the production of several proinflammatory cytokines responsible for insulin resistance. Psoriasis is a chronic relapsing inflammatory skin disease and is characterized by the increased release of pro-inflammatory cytokines, which can contribute to different pathological conditions within the spectrum of MS. A link between metabolic disorders and Psoriasis has emerged from evidence indicating that weight loss obtained through healthy diets and exercise was able to improve the clinical course and therapeutic response of Psoriasis in patients with obesity or overweight patients and even prevent its occurrence. A key factor in this balance is the gut microbiota; it is an extremely dynamic system, and this makes its manipulation through diet possible via probiotic, prebiotic, and symbiotic compounds. Given this, the gut microbiota represents an additional therapeutic target that can improve metabolism in different clinical conditions.
A 4-year-old boy was referred to our tertiary hospital after a penetrating adnexal injury by a large-breed dog to the left orbital area. There was an increase in lacrimation, which was thought to be due to an inflammatory reaction. However, it was discovered that the lacrimation increased in the reverse-Trendelenburg position and with the Valsalva maneuver. Halo sign and beta transferrin test were positive, which led to the diagnosis of cerebrospinal fluid (CSF) fistula, and the patient was operated using a supraorbital craniotomy. A dural tear was visualized and sutured appropriately, then fibrin glue and an autologous galeal graft were applied to the tear. The CSF oculorrhea stopped postoperatively, and the patient was discharged after 10 days of follow-up. The patient had no recurrent CSF leakage at 4-year follow-up. Although CSF oculorrhea is rare and may be difficult to discern from lacrimation, the presence of pneumocephalus and halo sign should suggest fistula repair.
A full-thickness muco-periosteal flap is reflected on the buccal side (crestal incision and two vertical releasing incisions). Near the base of mucoperiosteal flap, the periosteum is incised less than 0.5mm in depth, creating two segments, "coronal segment" and "apical segment," of the periosteal flap. The shallow incision helps in preventing damage to the submucosal layer. The flap is pulled with a pair of periodontal forceps laterally. Subsequently, the "lateral stretching" of the coronal segment of the flap is performed by applying pressure using the blunt face of scalpel blade with sweeping motion to allow flap advancement.
The invention provides a composite auxiliary material which is spherical or spherical-like particles obtained by virtue of co-crystallization between mannitol and crospovidone. The properties of fluidity, compressibility and the like of the compound auxiliary material meet requirements of a direct tablet compressing process. The invention also provides a preparation method of the composite auxiliary material. The preparation method comprises the following steps: adding a crospovidone suspension into a mannitol saturated solution; performing co-crystallization on mannitol and crospovidon in an ice water bath while stirring; and when the crystallization of mannitol is finished, performing suction filtration, drying, grinding and screening to obtain the composite auxiliary material which is the spherical or spherical-like particles obtained by virtue of co-crystallization between mannitol and crospovidone. The preparation method of the composite auxiliary material is simple in process and low in cost, and is beneficial for industrial production. The composite auxiliary material prepared by the method provided by the invention is used for preparing orally disintegrating tablets, and the disintegrating time of the prepared tablets is within 1 minute.
An embodiment of the invention may include a method, computer program product and computer system for object detection and identification. The method, computer program product and computer system may include computing device which may receive an image from an imaging device. The image may be a medical image. The computing device may detect one or more potential indicators of disease in the image using a first algorithm and determine areas of potential disease in the image using an artificial intelligence algorithm. The computing device may determine a correlation between the determined areas of potential disease in the image and the one or more potential indicators of disease for the image. The computing device may, in response to determining a positive correlation, identify one or more of the potential indicators of disease for annotation and generate a report indicating one or more potential indicators of disease was found in the image.
PURPOSE:To suppress an objective error to an irreducible minimum in a short time when a change in the lapse of time in the capacity of the left ventricle is measured by executing approximation for the outline of the ventricle in each picture and measuring the capacity of the ventricle by using a conventional density method after the approximated outline is obtained. CONSTITUTION:A left ventricle capacity measuring means CPU 1 equally divides a distance mutually between the outlines of the both left ventricles in an extension end (ED), which is set in advance, of the left ventricle and a shrinkage end (ES) by a number, for which '1' is added to a picture (intermediate picture) from the ED to ES by using the picture, which is stored to a digital picture storage device 3, for the left ventricle of the heart. Then, the approximation of the outline of the left ventricle is executed concerning each intermediate picture by a straight line connecting the respective equal dividing points. The approximation is samely executed by the straight line for the set outline of the left ventricle in the ED picture. Then, the obtained respective approximated outlines of the left ventricle are regarded as the outlines of those pictures and the capacity of the left ventricle is calculated concerning each picture. After that, a curved line for the change in the lapse of time is displayed on a TV monitor 4. Thus, the objective error can be suppressed to the irreducible minimum and in such a case, the outline is set by an operator only concerning the two pictures of the ED and ES. Then, operation is made easy and speedy in comparison with conventional technique.
A 180 minutes hyperinsulinaemic euglycaemic-hypoglycaemic clamp in combination with an exercise session. The participants will be monitored with Holter-ECG throughout the entire clamp and plasma glucose will be measured every 5 minutes. Blood samples will be drawn and analysed for changes in electrolytes, counterregulatory hormones, coagulation status, inflammation, endothelial damage and oxidative stress.
In this condition, participants are not exposed to any sound. The infrasound dummy source is placed close to the participant's bed, exactly like in the Infrasound - verum condition (1-2 meters). The Infrasound dummy source looks exactly like the active infrasound source but produces no sound at all. Participants are told that this source emits sound for 8 constant hours during their night sleep.
ZYVOX has been associated with thrombocytopenia when used in doses up to and including 600 mg every 12 hours for up to 28 days. In Phase 3 comparator-controlled trials, the percentage of adult patients who developed a substantially low platelet count (defined as less than 75% of lower limit of normal and/or baseline) was 2.4% (range among studies: 0.3 to 10.0%) with ZYVOX and 1.5% (range among studies: 0.4 to 7.0%) with a comparator. In a study of hospitalized pediatric patients ranging in age from birth through 11 years, the percentage of patients who developed a substantially low platelet count (defined as less than 75% of lower limit of normal and/or baseline) was 12.9% with ZYVOX and 13.4% with vancomycin. In an outpatient study of pediatric patients aged from 5 through 17 years, the percentage of patients who developed a substantially low platelet count was 0% with ZYVOX and 0.4% with cefadroxil. Thrombocytopenia associated with the use of ZYVOX appears to be dependent on duration of therapy, (generally greater than 2 weeks of treatment). The platelet counts for most patients returned to the normal range/baseline during the follow-up period. No related clinical adverse events were identified in Phase 3 clinical trials in patients developing thrombocytopenia. Bleeding events were identified in thrombocytopenic patients in a compassionate use program for ZYVOX; the role of linezolid in these events cannot be determined (see WARNINGS).

Changes seen in other laboratory parameters, without regard to drug relationship, revealed no substantial differences between ZYVOX and the comparators. These changes were generally not clinically significant, did not lead to discontinuation of therapy, and were reversible. The incidence of adult and pediatric patients with at least one substantially abnormal hematologic or serum chemistry value is presented in Tables 10, 11, 12, and 13.
Opioid use disorder is a national health emergency. Opioid prescribing practices to treat post-operative pain have contributed to the problem. This study seeks to explore the effects of changing pre-operative education \& increasing patient input regarding post-operative receipt of opioids. The study will explore the effects that change in pre-operative education may have on post-operative opioid consumption juxtaposed upon return to physical activity using a randomized trial design. Women undergoing pelvic floor reconstructive surgery will be randomized to either (i) standard pre-operative education (ii) modified, patient-centered pre-operative education. The investigators will monitor both post-operative opioid consumption and return to physical activity. The investigators hypothesize that investigation of patient's post-operative pain experiences and their inclusion in the educational and the shared decision-making process will likely decrease post-operative narcotic use without affecting return to function. Our long-term goal is to develop a pragmatic and balanced approach to address pain concerns, decreasing the medical community's contribution to the opioid epidemic.